Next-generation sequencing of cancer genomes: Back to the future

Personalized Medicine

Volumn 6, Issue 6, 2009, Pages 653-662

  Walter, Matthew J ^a   Graubert, Timothy A ^a   DiPersio, John F ^a   Mardis, Elaine R ^a   Wilson, Richard K ^a   Ley, Timothy J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Array CGH; Cancer; Comparative genomic hybridization; Genomics; Next generation sequencing; SNP array

Indexed keywords

DNA FRAGMENT; TRANSCRIPTION FACTOR RUNX1;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER CLASSIFICATION; CANCER GENETICS; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CHROMATIN IMMUNOPRECIPITATION; CHROMOSOME TRANSLOCATION; CYTOGENETICS; DNA METHYLATION; EPIGENETICS; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; HEMATOPOIETIC STEM CELL; HUMAN; INHERITANCE; KARYOTYPE; LEUKEMIA CELL; NONHUMAN; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 72449209239     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.09.52     Document Type: Review

References (50)

1. von Hansemann D: Ueber asymmetrische Zelltheilung in epithel Krebsen und deren biologische Bedeutung. Virchow's Arch. Path. Anat. 119, 299 (1890).
2. Nowell PC, Hungerford DA: A minute chromosome in human granulocytic leukemia. Science 132, 1497 (1960).
3. Rowley JD: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243(5405), 290-293 (1973).
4. Zech L, Haglund U, Nilsson K, Klein G: Characteristic chromosomal abnormalities in biopsies and lymphoid-cell lines from patients with Burkitt and non-Burkitt lymphomas. Int. J. Cancer 17(1), 47-56 (1976).
5. Rowley JD: Identificaton of a translocation with quinacrine fluorescence in a patient with acute leukemia. Ann. Genet. 16(2), 109-112 (1973).
6. Le Beau MM, Larson RA, Bitter MA, Vardiman JW, Golomb HM, Rowley JD: Association of an inversion of chromosome 16 with abnormal marrow eosinophils in acute myelomonocytic leukemia. A unique cytogenetic-clinicopathological association. N. Engl. J. Med. 309(11), 630-636 (1983).
7. Larson RA, Kondo K, Vardiman JW, Butler AE, Golomb HM, Rowley JD: Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia. Am. J. Med. 76(5), 827-841 (1984). (Pubitemid 14142683)
8. Fukuhara S, Rowley JD, Variakojis D, Golomb HM: Chromosome abnormalities in poorly differentiated lymphocytic lymphoma. Cancer Res. 39(8), 3119-3128 (1979). (Pubitemid 9226928)
9. Grimwade D, Walker H, Oliver F et al.: The importance of diagnostic cytogenetics on outcome in AML: ana lysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 92(7), 2322-2333 (1998).
10. Byrd JC, Mrozek K, Dodge RK et al.: Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100(13), 4325-4336 (2002). (Pubitemid 35429670)
11. Rucker FG, Bullinger L, Schwaenen C et al.: Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular characterization. J. Clin. Oncol. 24(24), 3887-3894 (2006). (Pubitemid 46630736)
12. Suela J, Alvarez S, Cifuentes F et al.: DNA profiling ana lysis of 100 consecutive de novo acute myeloid leukemia cases reveals patterns of genomic instability that affect all cytogenetic risk groups. Leukemia 21(6), 1224-1231 (2007). (Pubitemid 46831812)
13. Tyybakinoja A, Elonen E, Piippo K, Porkka K, Knuutila S: Oligonucleotide array-CGH reveals cryptic gene copy number alterations in karyotypically normal acute myeloid leukemia. Leukemia 21(3), 571-574 (2007). (Pubitemid 46306576)
14. Walter MJ, Payton JE, Ries RE et al.: Acquired copy number alterations in adult acute myeloid leukemia genomes. Proc. Natl Acad. Sci. USA 106(31), 12950-12955 (2009). ■ A copy number alteration study in adult de novo acute myeloid leukemia (AML) that identified an average of 2.34 changes per genome using paired normal and tumor samples with secondary validation of altered loci.
15. Radtke I, Mullighan CG, Ishii M et al.: Genomic ana lysis reveals few genetic alterations in pediatric acute myeloid leukemia. Proc. Natl Acad. Sci. USA 106(31), 12944-12949 (2009). ■ Pediatric AML copy number alteration study that identified an average of 2.38 alterations per genome.
16. Schlenk RF, Dohner K, Krauter J et al.: Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N. Engl. J. Med. 358(18), 1909-1918 (2008). ■ Landmark study demonstrating that the mutational status of NPM1, FLT3, CEBPA, and MLL in cytogenetically normal AML are associated with treatment outcome.
17. Baldus CD, Mrozek K, Marcucci G, Bloomfield CD: Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise review. Br. J. Haematol. 137(5), 387-400 (2007). (Pubitemid 46698282)
18. Bullinger L, Dohner K, Bair E et al.: Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N. Engl. J. Med. 350(16), 1605-1616 (2004). ■ Landmark study using gene-expression profiling to identify specific subgroups of AML that had prognostic significance. (Pubitemid 38501163)
19. Heuser M, Beutel G, Krauter J et al.: High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. Blood 108(12), 3898-3905 (2006). (Pubitemid 44864574)
20. Langer C, Radmacher MD, Ruppert AS et al.: High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. Blood 111(11), 5371-5379 (2008).
21. Lugthart S, van Drunen E, van Norden Y et al.: High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood 111(8), 4329-4337 (2008).
22. Marcucci G, Maharry K, Whitman SP et al.: High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. J. Clin. Oncol. 25(22), 3337-3343 (2007). (Pubitemid 47325620)
23. Valk PJ, Verhaak RG, Beijen MA et al.: Prognostically useful gene-expression profiles in acute myeloid leukemia. N. Engl. J. Med. 350(16), 1617-1628 (2004). ■ Landmark study using gene-expression profiling to identify specific subgroups of AML that had prognostic significance.
24. Huang ME, Ye YC, Chen SR et al.: Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72(2), 567-572 (1988).
25. Druker BJ, Sawyers CL, Kantarjian H et al.: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344(14), 1038-1042 (2001). (Pubitemid 32267973)
26. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer Statistics, 2009. CA Cancer J. Clin. 59(4), 225-249 (2009).
27. Sjoblom T, Jones S, Wood LD et al.: The consensus coding sequences of human breast and colorectal cancers. Science 314(5797), 268-274 (2006). (Pubitemid 44571966)
28. Ley TJ, Mardis ER, Ding L et al.: DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 456(7218), 66-72 (2008). ■ First report of a completely sequenced cancer genome.
29. Mardis ER, Ding L, Dooling DJ et al.: Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 361(11), 1058-1066 (2009). ■■ Describes the complete sequence of a second cancer genome and is particularly notable for the discovery of a highly recurrent mutation that was not previously detected in this disease.
30. Schinzel AC, Hahn WC: Oncogenic transformation and experimental models of human cancer. Front. Biosci. 13, 71-84 (2008).
31. Stratton MR, Campbell PJ, Futreal PA: The cancer genome. Nature 458(7239), 719-724 (2009).
32. Birney E, Stamatoyannopoulos JA, Dutta A et al.: Identification and ana lysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 447(7146), 799-816 (2007). (Pubitemid 46920138)
33. Sarin S, Prabhu S, O'Meara MM, Pe'er I, Hobert O: Caenorhabditis elegans mutant allele identification by whole-genome sequencing. Nat. Methods 5(10), 865-867 (2008).
34. Shah SP, Kobel M, Senz J et al.: Mutation of FOXL2 in granulosa-cell tumors of the ovary. N. Engl. J. Med. 360(26), 2719-2729 (2009).
35. Campbell PJ, Stephens PJ, Pleasance ED et al.: Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat. Genet. 40(6), 722-729 (2008). ■ Landmark study using paired-end nextgeneration sequencing to detect copy number alterations (insertions, deletions, inversions and translocations) in cancer cells.
36. Maher CA, Palanisamy N, Brenner JC et al.: Chimeric transcript discovery by paired-end transcriptome sequencing. Proc. Natl Acad. Sci. USA 106(30), 12353-12358 (2009).
37. Robertson G, Hirst M, Bainbridge M et al.: Genome-wide profiles of STAT1 DNA association using chromatin immunoprecipitation and massively parallel sequencing. Nat. Methods 4(8), 651-657 (2007). (Pubitemid 47202477)
38. Mardis ER: ChIP-seq: welcome to the new frontier. Nat. Methods 4(8), 613-614 (2007).
39. Song WJ, Sullivan MG, Legare RD et al.: Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat. Genet. 23(2), 166-175 (1999).
40. Smith ML, Cavenagh JD, Lister TA, Fitzgibbon J: Mutation of CEBPA in familial acute myeloid leukemia. N. Engl. J. Med. 351(23), 2403-2407 (2004).
41. Pabst T, Eyholzer M, Haefliger S, Schardt J, Mueller BU: Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia. J. Clin. Oncol. 26(31), 5088-5093 (2008).
42. Owen C, Barnett M, Fitzgibbon J: Familial myelodysplasia and acute myeloid leukaemia - a review. Br. J. Haematol. 140(2), 123-132 (2008). (Pubitemid 350265048)
43. Sellick GS, Pritchard-Jones K, Shepherd V, Swansbury J, Catovsky D, Houlston RS: Loci other than 21q22.12 (RUNX1) and 16q21-23.2 cause familial AML. Leukemia 19(3), 465-466 (2005). (Pubitemid 40403329)
44. Li FP, Fraumeni JF Jr, Mulvihill JJ et al.: A cancer family syndrome in twenty-four kindreds. Cancer Res. 48(18), 5358-5362 (1988).
45. Side L, Taylor B, Cayouette M et al.: Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis Type 1 and malignant myeloid disorders. N. Engl. J. Med. 336(24), 1713-1720 (1997). (Pubitemid 27251785)
46. Taylor AM, Metcalfe JA, Thick J, Mak YF: Leukemia and lymphoma in ataxia telangiectasia. Blood 87(2), 423-438 (1996).
47. Perry GS 3rd, Spector BD, Schuman LM et al.: The Wiskott-Aldrich syndrome in the United States and Canada (1892-1979). J. Pediatr. 97(1), 72-78 (1980).
48. Lichtenstein P, Holm NV, Verkasalo PK et al.: Environmental and heritable factors in the causation of cancer - analyses of cohorts of twins from Sweden, Denmark, and Finland. N. Engl. J. Med. 343(2), 78-85 (2000). (Pubitemid 30451850)
49. Goldstein DB: Common genetic variation and human traits. N. Engl. J. Med. 360(17), 1696-1698 (2009).
50. Pharoah PD, Dunning AM, Ponder BA, Easton DF: Association studies for finding cancer-susceptibility genetic variants. Nat. Rev. Cancer 4(11), 850-860 (2004).